NCT04174352: FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer

Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: ESR1
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Early Phase 1
Drug Category: Endocrine (hormone therapy, Other

Key Eligibility Criteria:

Gender: All
Age: 19 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have received at least 1 prior line of non-tamoxifen containing endocrine therapy in the metastatic setting or have had progression within 12 months of adjuvant non-tamoxifen endocrine therapy
Exclusions: Patients with unstable, symptomatic, uncontrolled brain metastases- see trial for details

Comments are closed.

Up ↑